Economic Outcomes of Dalbavancin versus Standard Therapy in Staphylococcus aureus Bacteremia in the DOTS Randomized Clinical Trial.

Reed SD, Li Y, Turner NA, Pasquale DK, Drew R, Cook P, Zaharoff S, Fowler VG Jr, Holland TL, Antibacterial Resistance Leadership Group

Open source

DOI: 10.1093/cid/ciag567
Published: 2026 Sep 17
Container: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/cid/ciag567,
  title = {Economic Outcomes of Dalbavancin versus Standard Therapy in Staphylococcus aureus Bacteremia in the DOTS Randomized Clinical Trial.},
  author = {Reed SD and Li Y and Turner NA and Pasquale DK and Drew R and Cook P and Zaharoff S and Fowler VG Jr and Holland TL and Antibacterial Resistance Leadership Group},
  year = {2026},
  journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  doi = {10.1093/cid/ciag567},
  url = {https://doi.org/10.1093/cid/ciag567}
}

RIS

TY  - JOUR
TI  - Economic Outcomes of Dalbavancin versus Standard Therapy in Staphylococcus aureus Bacteremia in the DOTS Randomized Clinical Trial.
AU  - Reed SD
AU  - Li Y
AU  - Turner NA
AU  - Pasquale DK
AU  - Drew R
AU  - Cook P
AU  - Zaharoff S
AU  - Fowler VG Jr
AU  - Holland TL
AU  - Antibacterial Resistance Leadership Group
PY  - 2026
JO  - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
DO  - 10.1093/cid/ciag567
UR  - https://doi.org/10.1093/cid/ciag567
ER  -

APA

SD, R., Y, L., NA, T., DK, P., R, D., P, C., S, Z., Jr, F. V., TL, H., & Group, A. R. L. (2026). Economic Outcomes of Dalbavancin versus Standard Therapy in Staphylococcus aureus Bacteremia in the DOTS Randomized Clinical Trial.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciag567

Source records

pubmed · retrieved 2026-09-25T09:11:20.960Z